Cubist Pharmaceuticals, Inc., which we refer to as "Cubist" or the "Company", is a biopharmaceutical company focused on the research, development and commercialization of products that address unmet medical needs in the acute care environment. Cubist is a U.S. corporation and was incorporated in Delaware in 1992. We completed our initial public offering in 1996, and our shares are listed on NASDAQ, where our symbol is CBST. Our principal offices are located at 65 Hayden Avenue, Lexington, Massachusetts. Our telephone number is 781-860-8660, and our website address is www.cubist.com. To date, we have been exclusively focused on developing business and product opportunities in the antiinfective marketplace. CUBICIN, our flagship drug, was approved on September 12, 2003, by the Food and Drug Administration (FDA) for sale in the United States.     

Flash Player 9 or higher is required to view the chart
Click here to download Flash Player now